Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications - PubMed (original) (raw)

Review

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications

Richard M Bergenstal et al. Am J Med. 2010 Apr.

Abstract

The selection of appropriate pharmacologic therapy for any disease requires a careful assessment of benefit and risk. In the case of type 2 diabetes, this decision typically balances the benefits accrued from improved glycemic control with the risks inherent in glucose-lowering medications. This review is intended to assist therapeutic decision-making by carefully assessing the potential benefit from improved metabolic control relative to the potential risks of a wide array of currently prescribed glucose-lowering agents. Wherever possible, risks and benefits have been expressed in terms of absolute rates (events per 1000 patient-years) to facilitate cross-study comparisons. The review incorporates data from new studies (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, Action to Control Cardiovascular Risk in Diabetes, and the Veterans Affairs Diabetes Trial), as well as safety issues associated with newer glucose-lowering medications.

PubMed Disclaimer

Similar articles

• ADVANCE: action in diabetes and vascular disease.
  Patel A, Chalmers J, Poulter N. Patel A, et al. J Hum Hypertens. 2005 Jun;19 Suppl 1:S27-32. doi: 10.1038/sj.jhh.1001890. J Hum Hypertens. 2005. PMID: 16075030 Review.
• Glycemic targets for patients with type 2 diabetes mellitus.
  Hamnvik OP, McMahon GT. Hamnvik OP, et al. Mt Sinai J Med. 2009 Jun;76(3):227-33. doi: 10.1002/msj.20117. Mt Sinai J Med. 2009. PMID: 19421966
• Pharmacologic management of the patient with type 2 diabetes.
  Quinn L. Quinn L. Nurs Clin North Am. 2001 Jun;36(2):217-42, vi. Nurs Clin North Am. 2001. PMID: 11382561 Review.
• [Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?].
  Mauricio D, Rius F. Mauricio D, et al. Med Clin (Barc). 2010 Sep;135 Suppl 2:2-5. doi: 10.1016/S0025-7753(10)70025-7. Med Clin (Barc). 2010. PMID: 21420530 Review. Spanish.
• Implications of new diabetes treatment trials: should current clinical practice be altered?
  Kravetz JD, Federman DG. Kravetz JD, et al. Postgrad Med. 2009 May;121(3):67-72. doi: 10.3810/pgm.2009.05.2004. Postgrad Med. 2009. PMID: 19491542 Review.

Cited by

• An Algorithm for Generating Individualized Treatment Decision Trees and Random Forests.
  Doubleday K, Zhou H, Fu H, Zhou J. Doubleday K, et al. J Comput Graph Stat. 2018;27(4):849-860. doi: 10.1080/10618600.2018.1451337. Epub 2018 Jun 14. J Comput Graph Stat. 2018. PMID: 32523325 Free PMC article.
• Effect of Olea europaea leaves extract on streptozotocin induced diabetes in male albino rats.
  Al-Attar AM, Alsalmi FA. Al-Attar AM, et al. Saudi J Biol Sci. 2019 Jan;26(1):118-128. doi: 10.1016/j.sjbs.2017.03.002. Epub 2017 Mar 7. Saudi J Biol Sci. 2019. PMID: 30622415 Free PMC article.
• Anti-diabetic medications: How to make a choice?
  Babiker A, Al Dubayee M. Babiker A, et al. Sudan J Paediatr. 2017;17(2):11-20. doi: 10.24911/SJP.2017.2.12. Sudan J Paediatr. 2017. PMID: 29545660 Free PMC article. Review.
• Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).
  Schernthaner G, Khunti K, Lotan C, Burnier M, Drexel H, Prázný M. Schernthaner G, et al. Ther Clin Risk Manag. 2017 Dec 13;13:1569-1576. doi: 10.2147/TCRM.S144362. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 29276388 Free PMC article.
• Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.
  Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC. Cefalu WT, et al. Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057. Diabetes Care. 2018. PMID: 29263194 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information